BioCryst Pharmaceuticals FY Conference Summary Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS: BCRX) - **Event**: FY Conference held on January 12, 2026 - **Key Speakers**: Charlie Gayer (CEO), Babar Ghias (CFO), Dr. Bill Sheridan (Chief Development Officer) Core Industry and Company Insights Industry: Rare Disease Pharmaceuticals - BioCryst focuses on developing treatments for rare diseases, particularly hereditary angioedema (HAE) Key Developments in 2025 - **ORLADEYO Growth**: Achieved the highest number of new patient prescriptions in the U.S. since its launch, with a paid rate improvement ending Q1 at 84% and the year at 81% compared to a long-term goal of 85% [3][4] - **European Business Sale**: Sold the European business for $250 million to streamline operations and focus on U.S. growth [3][4] - **Profitability**: Achieved profitability for the first time in company history, with expectations to maintain profitability moving forward [4] - **New Approval**: Received approval for ORLADEYO for children as young as two years old, expanding the market potential [4] Financial Performance - **2025 Preliminary Results**: - ORLADEYO revenue: $601 million, exceeding guidance of $590-$600 million - Ongoing business revenue (excluding European business): $563 million - Cash position: Nearly $340 million [5] - **2026 Revenue Guidance**: Anticipating ORLADEYO revenue of $625-$645 million and total revenue (including RAPIVAB) of $635-$660 million [5] Growth Strategy - **Three Pillars for Growth**: 1. **ORLADEYO**: Expected to reach $1 billion in peak sales by 2029 with a contribution margin over 80% [6] 2. **Novanavart**: Acquired through Astria Therapeutics, expected to enhance the portfolio with a differentiated injectable product [4][12] 3. **Netherton Syndrome Program**: Aiming to develop a transformative therapy for a high-need rare disease with no current treatments [20][21] Market Dynamics - **HAE Market**: Competitive landscape with 10-11 approved products, but ORLADEYO remains the only oral prophylaxis option, which is a significant differentiator [28][29] - **Patient Retention**: Approximately 50% of patients remain on ORLADEYO after five years, indicating strong efficacy and satisfaction [9] Future Outlook - **Revenue Growth**: Projected 15% year-over-year CAGR for ORLADEYO through 2029, with additional contributions from Novanavart and international markets [11][30] - **Acquisition of Astria**: Expected to close soon, enhancing BioCryst's capabilities in the HAE space [12][26] - **Netherton Syndrome**: Initial proof of concept trial expected to provide data by the end of 2026, with potential for pivotal study thereafter [26][43] R&D and Pipeline - **BCX 17725 for Netherton Syndrome**: Entering initial proof of concept trials, with a focus on safety and efficacy in patients [20][24] - **Avoralstat for Diabetic Macular Edema**: Currently in phase 1 study, with plans to out-license post-study completion [31][48] Conclusion - BioCryst Pharmaceuticals is positioned for significant growth in the rare disease market, with a strong focus on innovative therapies and strategic acquisitions. The company aims to leverage its successful commercialization strategies and maintain profitability while expanding its product offerings.

Financial Performance and Outlook - BioCryst achieved its first full year of profitability in 2025[13] - Preliminary ORLADEYO revenue for 2025 reached $601 million, with $563 million excluding European revenue[14] - The company anticipates ORLADEYO revenue between $625 million and $645 million in 2026[14] - Total revenue for 2026 is projected to be in the range of $635 million to $660 million[14] - Non-GAAP operating expenses for 2026 are expected to be between $380 million and $390 million, and $450 million to $470 million including the Astria acquisition[14] - BioCryst expects to have a cash balance of over $1 billion by 2029[37,52] Strategic Initiatives and Pipeline - BioCryst is acquiring Astria Therapeutics for approximately $700 million TEV to strengthen its HAE portfolio with navenibart[35] - ORLADEYO has a sustainable peak revenue opportunity of $1 billion, with IP protection extending into 2040[20] - The company received FDA approval for ORLADEYO pellet formulation for pediatric patients aged 2 to under 12 with HAE[13] - BCX17725 is being developed as a targeted KLK5 inhibitor for Netherton syndrome, with Phase 1 data from Part 4 expected by the end of 2026[54,69]

Core Insights - BioCryst Pharmaceuticals reported a transformative year in 2025, driven by strong demand for ORLADEYO and successful business maneuvers, including the sale of its European ORLADEYO business and the proposed acquisition of Astria Therapeutics [2] Financial Performance - Preliminary, unaudited ORLADEYO net revenue for full year 2025 was $601 million, reflecting a 37% year-over-year increase, surpassing prior guidance of $590 million to $600 million [4] - Excluding European ORLADEYO revenue, the net revenue for 2025 was $563 million, marking a 43% year-over-year growth on a comparable basis [4] - For the fourth quarter of 2025, ORLADEYO net revenue was $151 million, representing a 22% year-over-year increase, and a 36% increase on a comparable basis [3] Revenue Guidance - The company anticipates full year 2026 global net ORLADEYO revenue to be between $625 million and $645 million [5] - Total revenue for 2026, including RAPIVAB®, is expected to range from $635 million to $660 million [5] Operating Expenses - BioCryst expects full year 2026 non-GAAP operating expenses to be between $380 million and $390 million, excluding stock-based compensation and other costs [6] - After the expected acquisition of Astria, additional non-GAAP operating expenses in 2026 are projected to be between $70 million and $80 million [7] Cash Position - As of December 31, 2025, the company reported preliminary cash, cash equivalents, restricted cash, and investments totaling $338 million [5]

Group 1 - BioCryst Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 1:30 p.m. ET [1] - The presentation will be accessible via a live audio webcast on BioCryst's website [1] Group 2 - BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases [2] - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor [2] - BioCryst is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases [2]

Core Insights - BioCryst Pharmaceuticals is focused on developing oral treatments for rare diseases, particularly with its drug ORLADEYO® targeting hereditary angioedema (HAE) [1] - H.C. Wainwright maintains a "Buy" rating for BioCryst, raising its price target from $30 to $32, reflecting confidence in the company's future performance [2] - The FDA's approval of ORLADEYO in an oral pellet formulation is a significant milestone, especially for children, as it addresses a critical need in managing HAE [3] Company Performance - BioCryst's stock is currently priced at $7.60, with a slight increase of 0.33% today, and has fluctuated between $7.57 and $7.92 [4] - The company's market capitalization is approximately $1.6 billion, with a trading volume of 1,923,583 shares today [4] Market Impact - The expanded approval of ORLADEYO is expected to enhance BioCryst's market presence by targeting a younger demographic, positioning the company to capture a larger share of the HAE market [5]

Core Insights - The U.S. Food and Drug Administration (FDA) has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 and older [1] Company Summary - BioCryst Pharmaceuticals has received FDA approval for a new oral pellet formulation of its drug, which is aimed at preventing hereditary angioedema attacks in pediatric patients [1]

Core Viewpoint - BioCryst Pharmaceuticals has received FDA approval for ORLADEYO, the first and only targeted oral prophylactic therapy for pediatric patients aged 2 to less than 12 years with hereditary angioedema (HAE) [1][4]. Group 1: Product Information - ORLADEYO is an oral pellet formulation designed for once-daily administration, providing a child-friendly method of treatment [1][6]. - The approval is based on positive interim data from the APeX-P clinical trial, which demonstrated early and sustained reductions in monthly attack rates for pediatric patients [5][7]. - ORLADEYO has been prescribed to over 3,500 patients in the U.S. since its initial launch for older patients [5]. Group 2: Market Context - Approximately 40% of children with HAE experience their first attack by age 5, highlighting the need for effective treatment options for younger patients [2]. - Prior to this approval, treatment options for children under 12 were limited to intravenous or subcutaneous methods, which can be burdensome [2][9]. - The new oral pellet formulation aims to alleviate the treatment burden and improve the quality of life for children with HAE and their caregivers [7][9]. Group 3: Regulatory and Future Plans - BioCryst has filed applications for ORLADEYO oral pellets with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency, with additional regulatory filings planned in other territories, including Canada [7][8]. - The company is committed to providing comprehensive support through its Empower Patient Services program, which assists patients and healthcare providers with various needs related to ORLADEYO [10].

Core Viewpoint - BioCryst Pharmaceuticals has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics, indicating progress towards the merger [1][2]. Group 1: Merger Details - The termination of the waiting period satisfies one of the conditions for the merger, with BioCryst expecting the merger to close in the first quarter of 2026, pending other customary closing conditions [2]. - BioCryst has filed a registration statement with the SEC, which includes a preliminary proxy statement of Astria and a preliminary prospectus of BioCryst regarding the merger [5][6]. Group 2: Company Overview - BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases, with a commitment to improving the lives of affected individuals [3]. - The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for various rare diseases [3].

Core Insights - BioCryst is experiencing significant revenue growth from its product ORLADEYO, with current revenues between $590 million and $600 million, projected to peak at $1 billion [3] - The company has a strong patent protection for ORLADEYO extending to 2040, which supports its growth trajectory [3] - BioCryst has a pipeline that includes two clinical candidates: 17725 for Netherton syndrome and avoralstat for DME [3] - The company is in a favorable financial position, having proposed an acquisition of Astria [4]

Group 1 - Dyne Therapeutics has seen a significant increase in its stock price, rising 11% week-to-date, following a positive mention in an analyst note regarding the biotech sector [1][2][3] - The analyst note from RBC Capital Markets highlighted the strong performance of biotech companies in the third quarter of the year, indicating a favorable outlook for the sector [3][4] - The report suggested that many investors are shifting their focus from AI/tech stocks to biotech, which may lead to further growth opportunities in the sector [4][5] Group 2 - Dyne Therapeutics specializes in developing therapies for muscle disorders, particularly targeting myotonic dystrophy, with an estimated addressable patient population of around 95,000 in the U.S. and EU [6][7] - The potential customer base for Dyne's leading candidate, zeleciment basivarsen, presents a significant opportunity for the company [6][7] - Despite the positive outlook, Dyne Therapeutics was not included in a list of the top 10 stocks recommended by The Motley Fool Stock Advisor, indicating some caution among analysts [8][9]